

28 May 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo's oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept's NASH drug; and India's improving environment for clinical trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 May 2023, including: novel [Bristol Myers Squibb Company](#) drug shows promise in IPF; [Novo Nordisk A/S](#)'s oral semaglutide compares well with injectable in weight loss; [Teva Pharmaceutical Industries Ltd.](#) looks to innovative brands to return to growth; US setback for [Intercept Pharmaceuticals, Inc.](#)'s NASH drug; and India's improving environment for clinical trials.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[BMS Trumpets Breakthrough For Phase III-Bound IPF Drug](#)" - Scrip, 23 May, 2023.)

(Also see "[Novo's Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III](#)" - Scrip, 22 May, 2023.)

(Also see "[Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy](#)" - Scrip, 18 May, 2023.)

(Also see "[\*What Does The Negative FDA Review For Intercept's OCA Hold For Other NASH Drugs?\*](#)" - Scrip, 23 May, 2023.)

(Also see "[\*India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change\*](#)" - Scrip, 22 May, 2023.)

[Click here to explore this interactive content online](#) 